Pfizer Inc

NYSE: PFE
$25.85
+$0.08 (+0.3%)
Real Time Data Delayed 15 Min.

PFE Articles

Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety and income.
These are the 10 stocks tracked by 24/7 Wall St. that received multiple analyst rating upgrades or price target hikes of Wednesday, January 31, 2018.
The top analyst upgrades, downgrades and other research calls from Wednesday include AK Steel, Apple, Biogen, Electronic Arts, FitBit, Foot Locker, McDonald's and Pfizer.
UnitedHealth, Pfizer, McDonald's, and General Electric put in a dismal day and led the DJIA to steep loss Tuesday.
Pharmaceuticals giant Pfizer beat quarterly and full-year expectations this morning, but the beats were small and the forecast for next year is not exhilarating.
24/7 Wall St. has put together a preview of Exxon, Apple, Pfizer and other the Dow Jones Industrial Average companies scheduled to report their quarterly results this week.
Intel, Pfizer, 3M, and Disney launched the DJIA to a solid gain Friday.
The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Apple indicated that it will pay $38 billion in repatriation taxes under the new tax law. Apple says that it is already the largest U.S. taxpayer and that a payment of that size likely would be the...
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
UnitedHealth, Disney, Pfizer, and General Electric were Monday's laggards among the DJIA stocks.
For the Jones Industrial Average to make its 2018 targets, Pfizer and Merck will to have to do their part to help. But they both lagged the markets in 2017.
Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer.
Here is a consensus forecast of each of the 30 Dow Jones Industrial stocks, including a forward 12-month consensus analyst price target and an expected 2018 total return on each.
The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.